Cell and gene therapies are currently at the forefront of scientific innovation. They hold great promise for patients suffering from a range of serious ailments.

In this digital age, how can pharmaceutical manufacturers leverage innovative tools to prove their product's value proposition and overcome market access challenges?

What does Medicare claims data reveal about physician-administered drugs? An Xcenda survey reveals whether physicians choose treatment based on how much they're reimbursed.

An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.

An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.

How can manufacturers approach reimbursement and patient support for cell and gene therapies and other medical innovations?

What information do payers and providers want from pharma?

How are payers thinking about apps, wearables and other digital health technologies?

Understanding the unique considerations for reimbursement in the Canadian pharmaceutical market.

Learn what it takes to design an effective commercialization strategy and execute an integrated solution when the patient is in the supply chain.